NCT07348341|Recruiting
Coronary Laser Atherectomy Registry From an International Taskforce
CLARIT
Loading search results
CLARIT
Sponsor study identifier
observational
500
1 country
1
Study Start
July 20, 2026
Actual (reported)Primary Completion
July 30, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
July 30, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This study is a prospective, investigator-initiated, multi-center, single arm, observational registry of performance of Excimer Laser Coronary Atherectomy (ELCA) in standard use cases of percutaneous coronary intervention (PCI).
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 30, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 17, 2025
Actual (reported)January 16, 2026
Actual (reported)July 20, 2026
Actual (reported)July 30, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
July 30, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Procedural success during index PCI
The primary endpoint of efficacy is procedural Success during index PCI:, which is a combined endpoint of these following events: * Angiographic success defined as residual stenosis \<30% in two orthogonal projections after lesion treatment with ELCA destination therapy with DES or DCB * TIMI 3 flow and absence of ELCA related complications during the procedure * Intra-Coronary Imaging success defined as final MSA \> 5.5mm2 IVUS or 4.5mm2 OCT with \> 80% stent expansion - site reported
During Procedure
Freedom from in hospital Major Adverse Cardiovascular Events
The primary endpoint of safety is freedom from in-hospital Major Adverse Cardiovascular Events (MACE), including : cardiac death, target vessel myocardial infarction (TVMI), urgent repeat target vessel revascularization (TVR) with either PCI or CABG, and Stroke.
Periprocedural
Composite endpoint of one of events reported
30 days and 1 year
Success of revascularization: Freedom from Target lesion failure (TLF) events and ICI assessed stent optimization
30 days and 1 year
Procedural Characteristic- Cost
During procedure
Procedural Characteristic- Device success based on maximum fluence
During procedure
Procedural Characteristic- Fluoroscopy Time
During procedure
ELCA treat a significant coronary stenosis or recanalize occluded coronary arteries using UV during percutaneous coronary intervention.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients with stable coronary artery disease or acute coronary syndromes who will be treated with excimer laser coronary atherectomy (ELCA)
La Paz Universtity Hospital
Madrid, Spain
Peter O'kane, Professor
Dorset Heart Centre, The Royal Bournemouth Hospital
First Submitted
November 17, 2025
First Posted
January 16, 2026
Study Start
July 20, 2026
Actual (reported)Primary Completion
July 30, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Contact the study team to confirm eligibility.
Study Completion
July 30, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
July 23, 2026
Record last verified: 2026-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: